Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20820178 | 0.79 | MAP4K4 (0.47) | MAP4K4TNIKRIPK1 | |
| SCHEMBL15740086 | 0.78 | MAP4K4 (0.46) | MAP4K4TNIKRIPK1PIK3CD | |
| SCHEMBL13075167 | 0.76 | MAP4K4 (0.44) | MAP4K4TNIKRIPK1 | |
| SCHEMBL868211 | 0.76 | CHRNA7 (0.34) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL17238976 | 0.76 | MAP4K4 (0.44) | MAP4K4CHRNA7HTR3ATNIKRIPK1 | |
| SCHEMBL6844956 | 0.76 | CHRNA7 (0.34) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL64667 | 0.76 | MAP4K4 (0.44) | MAP4K4CHRNA7HTR3ATNIKRIPK1 | |
| SCHEMBL22326695 | 0.74 | MAP4K4 (0.43) | MAP4K4TNIKRIPK1 | |
| SCHEMBL24236922 | 0.73 | MAP4K4 (0.42) | MAP4K4TNIKRIPK1PIK3CD | |
| SCHEMBL21137294 | 0.73 | MAP4K4 (0.42) | MAP4K4TNIKRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332996-B | L-ribofuranose type anti-coronavirus compound, and preparation method and application thereof | 南京颐媛生物医学研究院有限公司 | 2025-04-01 | — | — | CN | claimed |
| CN-117126199-B | Fluororad West-Wei synthesis method | 江西师范大学 | 2024-12-06 | — | — | CN | claimed |
| CN-117126199-A | Synthesis method of fluoroRuidexivir | 江西师范大学 | 2023-11-28 | — | — | CN | claimed |
| CN-116478171-A | Simple preparation method of 4-amino-7-halogenopyrrolo [2, l-f ] [ l,2,4] triazine | 威海同丰海洋生物科技有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-116332996-A | Anti-coronavirus compound, preparation method and application thereof | 南京颐媛生物医学研究院有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-111205327-B | Preparation method of Reideciclovir | 南京法恩化学有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-111205327-A | Preparation method of Reidesciclovir | 南京法恩化学有限公司 | 2020-05-29 | — | — | CN | claimed |
| CN-110776512-A | Preparation method of nucleoside analogue | 成都傲飞生物化学品有限责任公司 | 2020-02-11 | — | — | CN | claimed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4719606-A2 | GCN2 AND PERK KINASE MODULATORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12583879-B2 | Method for synthesizing C-nucleoside compound | SICHUAN UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4705313-A2 | 4'-SUBSTITUTED NUCLEOSIDES AND NUCLEOTIDES AS ANTIVIRAL AGENTS | The Scripps Research Institute (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12558364-B2 | Next generation remdesivir antivirals | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2026-02-24 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| EP-1957485-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Healthcare, LLC (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064931-A2 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558364-B2 | Next generation remdesivir antivirals | SARS1, ACE2, ACE | MAP4K4 1377/4885CHRNA7 2519/4885HTR3A 824/4885 |
| US-12583879-B2 | Method for synthesizing C-nucleoside compound | MTAP, NSUN2, BCDIN3D | MAP4K4 3669/4885CHRNA7 2052/4885HTR3A 1732/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MAP4K4 1512/4885CHRNA7 2372/4885HTR3A 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.